{
    "nct_id": "NCT02947347",
    "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Na√Øve Subjects With Follicular Lymphoma (PERSPECTIVE)",
    "inclusion_criteria": "* Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.\n* Measurable disease\n* Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.\n* Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.\n* Adequate hematologic function within protocol-defined parameters.\n* Adequate hepatic and renal function within protocol-defined parameters.\n* ECOG performance status score of 0-2.\nHealthy volunteers allowed\nMust have minimum age of 60 Years",
    "exclusion_criteria": "* Transformed lymphoma\n* Prior treatment for follicular lymphoma.\n* Central nervous system lymphoma or leptomeningeal disease.\n* Currently active, clinically significant cardiovascular disease.",
    "miscellaneous_criteria": ""
}